Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naomi P Visanji

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|May 7, 2014
Novel transgenic technology reveals several molecular adaptations and potential therapeutic targets in the direct pathway in levodopa-induced dyskinesiaNaomi P Visanji
Movement Disorders : Official Journal of the Movement Disorder Society|April 13, 2023
The MonKEY to Unlocking the Pathogenesis of Progressive Supranuclear PalsySyeda Hania Qamar, Naomi P Visanji
Movement Disorders : Official Journal of the Movement Disorder Society|March 31, 2021
Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's DiseaseNaomi P Visanji, Anthony E Lang
Current Protocols in Pharmacology|September 29, 2011
MPTP-induced models of Parkinson's disease in mice and non-human primatesNaomi P Visanji, Jonathan M Brotchie
Frontiers in Neuroscience|October 18, 2024
Toward an animal model of Progressive Supranuclear PalsyPriyanka, Syeda Hania Qamar, Naomi P Visanji
Expert Opinion on Emerging Drugs|May 6, 2020
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an updateSohaila AlShimemeri, Susan H Fox, Naomi P Visanji
Neurology|November 11, 2015
Author responseNaomi P Visanji, Anthony E Lang, Lili-Naz Hazrai
Neuroscience Letters|November 15, 2017
Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathiesNaomi P Visanji, Anthony E Lang, David G Munoz
Translational Neurodegeneration|September 12, 2019
Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbiditiesNaomi P Visanji, Anthony E Lang, Gabor G Kovacs
Experimental Neurology|July 4, 2006
Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted ratsNaomi P Visanji, Mark J Millan, Jonathan M Brotchie
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Movement Disorders : Official Journal of the Movement Disorder Society|May 7, 2014
Novel transgenic technology reveals several molecular adaptations and potential therapeutic targets in the direct pathway in levodopa-induced dyskinesiaNaomi P Visanji
Movement Disorders : Official Journal of the Movement Disorder Society|April 13, 2023
The MonKEY to Unlocking the Pathogenesis of Progressive Supranuclear PalsySyeda Hania Qamar, Naomi P Visanji
Movement Disorders : Official Journal of the Movement Disorder Society|March 31, 2021
Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's DiseaseNaomi P Visanji, Anthony E Lang
Current Protocols in Pharmacology|September 29, 2011
MPTP-induced models of Parkinson's disease in mice and non-human primatesNaomi P Visanji, Jonathan M Brotchie
Frontiers in Neuroscience|October 18, 2024
Toward an animal model of Progressive Supranuclear PalsyPriyanka, Syeda Hania Qamar, Naomi P Visanji
Expert Opinion on Emerging Drugs|May 6, 2020
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an updateSohaila AlShimemeri, Susan H Fox, Naomi P Visanji
Neurology|November 11, 2015
Author responseNaomi P Visanji, Anthony E Lang, Lili-Naz Hazrai
Neuroscience Letters|November 15, 2017
Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathiesNaomi P Visanji, Anthony E Lang, David G Munoz
Translational Neurodegeneration|September 12, 2019
Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbiditiesNaomi P Visanji, Anthony E Lang, Gabor G Kovacs
Experimental Neurology|July 4, 2006
Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted ratsNaomi P Visanji, Mark J Millan, Jonathan M Brotchie
Pageof 8